10 results for "Baker CL"
Showing 1–10 · 0.42 seconds · RSS
-
Journal Article
A cost-effectiveness analysis of varenicline for smoking cessation using data from the EAGLES trial
Christine L Baker,1 Guilhem Pietri2 1Pfizer Inc., New York, NY, USA; 2Data Pyxis Ltd., St Albans, UK Background: The cost-effectiveness of varenicline has been demonstrated in the US health care setting using the Benefits of Smoking Cessation on Outcomes (BENESCO) model to simulate the lifetime…
-
Journal Article
Risk assessment of readmissions following an initial COPD-related hospitalization
Christine L Baker,1 Kelly H Zou,1 Jun Su2 1Pfizer Inc, New York, NY, USA; 2Boehringer-Ingelheim Pharmaceuticals Inc, Ridgefield, CT, USA Background: Acute exacerbation of chronic obstructive pulmonary disease (COPD) is a leading cause of hospitalizations and readmissions in the US. Reducing the…
-
Journal Article
Long-acting bronchodilator use after hospitalization for COPD: an observational study of health insurance claims data
Christine L Baker,1 Kelly H Zou,1 Jun Su21Pfizer Inc., New York, NY, USA; 2Boehringer-Ingelheim Pharmaceuticals Inc., Ridgefield, CT, USABackground: Treatment of stable chronic obstructive pulmonary disease (COPD) with long-acting bronchodilator (LABD) medications is recommended by the 2014 Global…
-
Journal Article Full text
The "motion-blind" patient: low-level spatial and temporal filters
The “motion-blind” patient previously described by Zihl et al. (1983) was investigated using standard psychophysical procedures with stimuli whose spatial and temporal properties could be separately manipulated. Detection experiments for sinewave grating stimuli of varying spatial and temporal…
-
Journal Article Full text
Residual motion perception in a "motion-blind" patient, assessed with limited-lifetime random dot stimuli
A neurological patient (L.M.) suffering a specific loss of visual motion perception (Zihl et al., 1983) due to extrastriate cortical damage was studied using random dot “limited-lifetime” stimuli with a direction discrimination task. With a stimulus like that of Newsome and Pare (1988), the patient…
-
Journal Article
Real-world characterization and differentiation of the Global Initiative for Chronic Obstructive Lung Disease strategy classification
David B Price,1 Christine L Baker,2 Kelly H Zou,3 Victoria S Higgins,4 James T Bailey,4 James S Pike4 1University of Aberdeen, Division of Applied Health Sciences, Aberdeen, UK; 2Pfizer Inc, Outcomes and Evidence, Global Health and Value, New York, USA; 3Pfizer Inc, Statistical Center for Outcomes…
-
Journal Article
A cost–benefit analysis of smoking cessation prescription coverage from a US payer perspective
Christine L Baker,1 Yao Ding,2 Cheryl P Ferrufino,2 Stacey Kowal,2 Jenen Tan,3 Prasun Subedi1 1Patient & Health Impact, Pfizer, Inc, New York, NY, USA; 2Health Economics & Outcomes Research, Real World Evidence Solutions, IQVIA, Fairfax, VA, USA; 3IQVIA, San Francisco, CA, USA Introduction: Smoking…
-
Journal Article
Outcomes associated with initiation of tiotropium or fluticasone/salmeterol in patients with chronic obstructive pulmonary disease
Rachel Halpern1, Christine L Baker2, Jun Su3, Kimberly B Woodruff2, Ryne Paulose-Ram2, Victoria Porter1, Hemal Shah41Health Economics and Outcomes Research, OptumInsight, Eden Prairie, MN, USA; 2Global Market Access, Primary Care Business Unit, Pfizer Inc, New York, NY, USA; 3Health Economics and…
-
Journal Article
Adjusting for COPD severity in database research: developing and validating an algorithm
Lucas MA Goossens1, Christine L Baker2, Brigitta U Monz3, Kelly H Zou2, Maureen PMH Rutten-van Mölken11Institute for Medical Technology Assessment, Erasmus University, Rotterdam, The Netherlands; 2Pfizer Inc, New York City, NY, USA; 3Boehringer Ingelheim International GmbH, Ingelheim am Rhein…
-
Journal Article
COPD exacerbations associated with the modified Medical Research Council scale and COPD assessment test among Humana Medicare members
Margaret K Pasquale,1 Yihua Xu,1 Christine L Baker,2 Kelly H Zou,3 John G Teeter,4 Andrew M Renda,5 Cralen C Davis,1 Theodore C Lee,6 Joel Bobula2 1Comprehensive Health Insights, Inc., Humana Inc., Louisville, KY, 2Outcomes and Evidence, Global Health & Value, Pfizer Inc., 3Statistical Center for…